Dexcom, Inc. (DXCM) — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Dexcom develops and markets continuous glucose monitoring (CGM) systems. Results are unaudited and prepared under U.S. GAAP. Unless stated otherwise, amounts are in millions of dollars.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $871.3 (+25%) | $696.2 | $1,612.8 (+22%) | $1,325.0 |
| Gross profit | $546.4 (+22%) | $449.5 | $1,009.0 (+19%) | $847.6 |
| Gross margin | 62.7% | 64.6% | 62.6% | 64.0% |
| Operating income | $128.1 (+66%) | $77.0 | $175.3 (+48%) | $118.3 |
| Net income | $115.9 (+128%) | $50.9 | $164.5 (+11%) | $148.2 |
| Diluted EPS | $0.28 | $0.12 | $0.40 | $0.36 |
- Q2 operating margin was approximately 14.7%, versus 11.1% a year earlier. Net margin was approximately 13.3%, versus 7.3%.
- Q2 operating cash flow was $190.3, up 10% year over year; first-half operating cash flow was $345.7, versus $243.8. First-half capital expenditures were $133.7, compared with $193.1.
- At June 30, cash and cash equivalents were $1,194.9 and short-term marketable securities were $2,441.3, totaling about $3.64 billion. Current assets were $5,002.9 and current liabilities $2,069.7; the company reported a 2.42 working-capital ratio and 2.12 quick ratio.
- Senior convertible notes had a $3,232.3 principal balance and $3,204.4 carrying amount. The company also had a $200.0 revolving facility, no borrowings, and $192.7 available after letters of credit. It reported compliance with facility covenants.
Changes and operating drivers
- Revenue growth was primarily driven by higher disposable sensor sales and worldwide customer growth. Disposable sensor and other revenue represented about 89% of sales, up from 86%; reusable hardware’s share declined from 14% to 11%.
- U.S. revenue rose to $616.6 from $511.0 in Q2; international revenue rose to $254.7 from $185.2. Distributors generated 85% of Q2 revenue, compared with 84% a year earlier.
- Gross margin fell as price, product and channel mix, intangible amortization, and foreign currency effects offset volume growth.
- Q2 R&D expense declined 2% to $119.3, while SG&A rose 19% to $297.3. Management attributed SG&A growth mainly to higher headcount, patent litigation costs, and increased marketing.
- Q2 interest and other income rose to $37.1 from $3.0, mainly due to higher interest income on cash and investments. This helped lift reported net income. First-half 2022 included a $36.8 income tax benefit; first-half 2023 recorded $59.3 of tax expense, affecting the year-over-year net-income comparison.
Outlook, risks, and notable items
- No revenue or earnings guidance is provided in the supplied filing text. Management expects existing liquidity and operating cash flows to fund operations and anticipated requirements for at least the next 12 months, and expects positive operating cash flow to continue.
- Management expects significant investment in manufacturing capacity, including Malaysia and Ireland and expansion in Mesa, Arizona. Scaling production efficiently and maintaining product supply and quality are key execution risks.
- The filing estimates a 28.5% full-year 2023 effective tax rate from normal recurring operations. The actual first-half rate was 26.5%.
- In Q2, holders converted $532.2 of 2023 Notes; Dexcom elected to pay principal in cash and any excess conversion value in shares, with settlement expected in Q3. A further $7.8 converted from July 1 through July 26. The 2023 Notes mature in December 2023.
- In May, Dexcom issued $1.25 billion of 0.375% notes due 2028, receiving net proceeds of about $1.23 billion. It spent $101.3 on capped calls and repurchased 1.6 million shares for $188.7 outside its share repurchase program. The program expired June 30, 2023.
- Abbott-related patent and contract disputes remain material uncertainties. A July 14, 2023 jury verdict found Abbott was not licensed to several claims of certain Dexcom patents but was licensed to a few claims. Other litigation continues, and the filing says ultimate outcomes cannot be reasonably estimated.
- Other principal risks include reimbursement and pricing pressure, competition, regulatory and product-quality requirements, cybersecurity and privacy, supply-chain and manufacturing constraints, international expansion, and convertible-debt repayment or dilution.
Investor verification priorities
- Track revenue growth, sensor mix, pricing and channel mix, and whether gross-margin pressure persists.
- Review subsequent filings for settlement of the converted 2023 Notes, remaining maturity obligations, and any share dilution or cash use.
- Monitor manufacturing expansion, capital spending, inventory growth, and the company’s ability to meet demand without quality or supply disruption.
- Follow Abbott litigation developments, including potential effects on intellectual property rights, product sales, costs, or injunction risk.
- Assess whether operating cash generation and the investment portfolio continue to support capital needs, debt obligations, and growth plans.